アレルギー性鼻副鼻腔炎に対する塩酸アゼラスチン(アゼプチン R)の臨床的評価

概要

論文の詳細を見る
Forty one patients with perennial allergic rhino-sinusitis were orally administered azelastin hydrochloride (Azeptin R) at a dose of 2 mg/day for 8 weeks. The clinical efficacy and the safety were evaluated.<BR>The clinical efficacy rate, which was estimated by the changes in the subjective symptoms and the objective findings including the roentgenographic changes in sinuses, was 53.7%.<BR>There were no patients who showed any side effects throughout the trial. The clinical availability rate, which was evaluated by the clinical efficacy and the satety, was 53.7%. The patients who showed a shadow larger than moderate in X-ray photos of the sinuses in the pretreatment state revealed a high improvement rate as demonstrated by X-ray findings in the maxillary sinuses (70.0%) and in the ethmoidal sinuses (75.0%).<BR>The patients who had nasal blockade as the main symptom showed a high clinical efficacy rate in comparison with the other patients.<BR>These findings revealed that azelastin ( A zepti R) had an excellent clinical efficacy with a high safety for the patients with allergic rhino-sinusitis. They also suggested that the high efficacy of azelastin especially in the patients showing mucosal swelling in the nasal cavity or sinuses might be attributable to the inhibitory action of azelastin for leukotrienes or leukotrienes' synthesis.
耳鼻咽喉科臨床学会の論文